1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. [
DOI:10.3322/caac.21660] [
PMID]
2. Wang X, Wang N, Zhong L, Wang S, Zheng Y, Yang B, et al. Prognostic value of depression and anxiety on breast cancer recurrence and mortality: a systematic review and meta-analysis of 282,203 patients. Mol Psychiatry. 2020;25(12):3186-97. [
DOI:10.1038/s41380-020-00865-6] [
PMID] [
PMCID]
3. Kabel AM. Tumor markers of breast cancer: New prospectives. J Oncol Sci. 2017;3(1):5-11. [
DOI:10.1016/j.jons.2017.01.001]
4. Obeagu EI, Obeagu GU. Breast cancer: A review of risk factors and diagnosis. Medicine. 2024;103(3):e36905. [
DOI:10.1097/MD.0000000000036905] [
PMID] [
PMCID]
5. Moseson M, Koenig KL, Shore RE, Pasternack BS. The Influence of Medical Conditions Associated with Hormones on the Risk of Breast Cancer. Int J Epidemiol. 1993;22(6):1000-9. [
DOI:10.1093/ije/22.6.1000] [
PMID]
6. Chowdhury FA, Islam MF, Prova MT, Khatun M, Sharmin I, Islam KM, et al. Association of hyperlipidemia with breast cancer in Bangladeshi women. Lipids Health Dis. 2021;20(1):52. [
DOI:10.1186/s12944-021-01480-2] [
PMID] [
PMCID]
7. Han H, Guo W, Shi W, Yu Y, Zhang Y, Ye X, et al. Hypertension and breast cancer risk: a systematic review and meta-analysis. Sci Rep. 2017;7(1):44877. [
DOI:10.1038/srep44877] [
PMID] [
PMCID]
8. Boyle P, Boniol M, Koechlin A, Robertson C, Valentini F, Coppens K, et al. Diabetes and breast cancer risk: a meta-analysis. Br J Cancer. 2012;107(9):1608-17. [
DOI:10.1038/bjc.2012.414] [
PMID] [
PMCID]
9. Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cífková R, Dominiczak AF, et al. Hypertension. Nat Rev Dis Primers. 2018;4:18014. [
DOI:10.1038/nrdp.2018.14] [
PMID] [
PMCID]
10. Farhadi F, Aliyari R, Ebrahimi H, Hashemi H, Emamian MH, Fotouhi A. Prevalence of uncontrolled hypertension and its associated factors in 50-74 years old Iranian adults: a population-based study. BMC Cardiovasc Disord. 2023;23(1):318. [
DOI:10.1186/s12872-023-03357-x] [
PMID] [
PMCID]
11. Kim KI. Hypertension in Older Women: The Biggest Challenge for Cardiovascular Health in an Aged Society. Korean Circ J. 2022;52(5):393-4. [
DOI:10.4070/kcj.2022.0036] [
PMID] [
PMCID]
12. Yankaskas BC. Epidemiology of breast cancer in young women. Breast Dis. 2005;23:3-8. [
DOI:10.3233/BD-2006-23102] [
PMID]
13. Williams MS, Beech BM, Griffith DM Jr, Thorpe RJ. The Association between Hypertension and Race/Ethnicity among Breast Cancer Survivors. J Racial Ethn Health Disparities. 2020;7(6):1172-7. [
DOI:10.1007/s40615-020-00741-7] [
PMID] [
PMCID]
14. Goldberg M, Díaz-Santana MV, O'Brien KM, Zhao S, Weinberg CR, Sandler DP. Gestational Hypertensive Disorders and Maternal Breast Cancer Risk in a Nationwide Cohort of 40,720 Parous Women. Epidemiology. 2022;33(6):868-79. [
DOI:10.1097/EDE.0000000000001511] [
PMID] [
PMCID]
15. Yue W, Tran HT, Wang JP, Schiermeyer K, Gildea JJ, Xu P, et al. The Hypertension Related Gene G-Protein Coupled Receptor Kinase 4 Contributes to Breast Cancer Proliferation. Breast Cancer (Auckl). 2021;15:11782234211015753. [
DOI:10.1177/11782234211015753] [
PMID] [
PMCID]
16. Wang W, He Q, Zhang H, Zhuang C, Wang Q, Li C, et al. A narrative review on the interaction between genes and the treatment of hypertension and breast cancer. Ann Transl Med. 2021;9(10):894. [
DOI:10.21037/atm-21-2133] [
PMID] [
PMCID]
17. Fan Y, Khan NH, Farhan Ali Khan M, Ahammad MDF, Zulfiqar T, Virk R, et al. Association of Hypertension and Breast Cancer: Antihypertensive Drugs as an Effective Adjunctive in Breast Cancer Therapy. Cancer Manag Res. 2022;14:1323-9. [
DOI:10.2147/CMAR.S350854] [
PMID] [
PMCID]
18. Mazzuferi G, Bacchetti T, Islam MO, Ferretti G. High density lipoproteins and oxidative stress in breast cancer. Lipids Health Dis. 2021;20(1):143. [
DOI:10.1186/s12944-021-01562-1] [
PMID] [
PMCID]
19. Ferroni P, Riondino S, Buonomo O, Palmirotta R, Guadagni F, Roselli M. Type 2 Diabetes and Breast Cancer: The Interplay between Impaired Glucose Metabolism and Oxidant Stress. Oxid Med Cell Longev. 2015;2015:183928. [
DOI:10.1155/2015/183928] [
PMID] [
PMCID]
20. Zhu H, Doğan BE. American Joint Committee on Cancer's Staging System for Breast Cancer, Eighth Edition: Summary for Clinicians. Eur J Breast Health. 2021;17(3):234-8. [
DOI:10.4274/ejbh.galenos.2021.2021-4-3] [
PMID] [
PMCID]
21. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334-57. [
DOI:10.1161/HYPERTENSIONAHA.120.15026] [
PMID]
22. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care. 2023;47(Supplement_1):S20-S42. [
DOI:10.2337/dc24-S002] [
PMID] [
PMCID]
23. Rezaianzadeh A, Namayandeh SM, Sadr SM. National Cholesterol Education Program Adult Treatment Panel III Versus International Diabetic Federation Definition of Metabolic Syndrome, Which One is Associated with Diabetes Mellitus and Coronary Artery Disease?. Int J Prev Med. 2012;3(8):552-8.
24. Weismiller DG. Menopause. Prim Care - Clin Off Pract. 2009;36(1):199-226. [
DOI:10.1016/j.pop.2008.10.007] [
PMID]
25. Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press). 2019;11(null):151-64. [
DOI:10.2147/BCTT.S176070] [
PMID] [
PMCID]
26. Kozłowska K, Kozłowski L, Małyszko J. Hypertension prevalence in early breast cancer patients undergoing primary surgery. Adv Med Sci. 2019;64(1):32-6. [
DOI:10.1016/j.advms.2018.10.003] [
PMID]
27. Ma J, Li Y, Yang X, Liu K, Zhang X, Zuo X, et al. Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8(1):168. [
DOI:10.1038/s41392-023-01430-7] [
PMID] [
PMCID]
28. Powe DG, Voss MJ, Zänker KS, Habashy HO, Green AR, Ellis IO, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget. 2010;1(7):628-38. [
DOI:10.18632/oncotarget.197] [
PMID] [
PMCID]
29. Wong GW, Boyda HN, Wright JM. Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension. Cochrane Database Syst Rev. 2016;3(3):Cd007451. [
DOI:10.1002/14651858.CD007451.pub2]
30. Madel MB, Elefteriou F. Mechanisms Supporting the Use of Beta-Blockers for the Management of Breast Cancer Bone Metastasis. Cancers (Basel). 2021;13(12):2887. [
DOI:10.3390/cancers13122887] [
PMID] [
PMCID]
31. Jung SY, Rosenzweig M, Sereika SM, Linkov F, Brufsky A, Weissfeld JL. Factors associated with mortality after breast cancer metastasis. Cancer Causes Control. 2012;23(1):103-12. [
DOI:10.1007/s10552-011-9859-8] [
PMID]
32. Ritte R, Lukanova A, Tjønneland A, Olsen A, Overvad K, Mesrine S, et al. Height, age at menarche and risk of hormone receptor-positive and -negative breast cancer: A cohort study. Int J Cancer. 2013;132(11):2619-29. [
DOI:10.1002/ijc.27913] [
PMID]
33. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13(11):1141-51. [
DOI:10.1016/S1470-2045(12)70425-4] [
PMID]
34. Yang P-J, Hou M-F, Ou-Yang F, Tsai E-M, Wang T-N. Association of early-onset breast cancer with body mass index, menarche, and menopause in Taiwan. BMC Cancer. 2022;22(1):259. [
DOI:10.1186/s12885-022-09361-2] [
PMID] [
PMCID]
35. Fuhrman BJ, Moore SC, Byrne C, Makhoul I, Kitahara CM, Berrington de González A, et al. Association of the Age at Menarche with Site-Specific Cancer Risks in Pooled Data from Nine Cohorts. Cancer Res. 2021;81(8):2246-55. [
DOI:10.1158/0008-5472.CAN-19-3093] [
PMID] [
PMCID]
36. Orgéas CC, Hall P, Rosenberg LU, Czene K. The influence of menstrual risk factors on tumor characteristics and survival in postmenopausal breast cancer. Breast Cancer Res. 2008;10(6):R107. [
DOI:10.1186/bcr2212] [
PMID] [
PMCID]
37. Subramaniam S, Kong YC, Zaharah H, Uiterwaal C, Richard A, Taib NA, et al. Baseline cardiovascular comorbidities, and the influence on cancer treatment decision-making in women with breast cancer. Ecancermedicalscience. 2021;15:1293. [
DOI:10.3332/ecancer.2021.1293] [
PMID] [
PMCID]
38. Henry Mariana L, Niu J, Zhang N, Giordano Sharon H, Chavez-MacGregor M. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients. JACC Cardiovasc Imaging. 2018;11(8):1084-93. [
DOI:10.1016/j.jcmg.2018.06.005] [
PMID] [
PMCID]
39. Clift AK, Dodwell D, Lord S, Petrou S, Brady SM, Collins GS, et al. The current status of risk-stratified breast screening. Br J Cancer. 2022;126(4):533-50. [
DOI:10.1038/s41416-021-01550-3] [
PMID] [
PMCID]
40. Patnaik JL, Byers T, DiGuiseppi C, Denberg TD, Dabelea D. The Influence of Comorbidities on Overall Survival Among Older Women Diagnosed With Breast Cancer. J Natl Cancer Inst. 2011;103(14):1101-11. [
DOI:10.1093/jnci/djr188] [
PMID] [
PMCID]